CSTX News

Cirius Therapeutics, a Phase 2 biotech developing therapies for NASH, withdrew its plans for an initial public offering on Friday. It originally filed in January 2019 with a proposed deal size of $86 million. The San Diego, CA-based company was founded in 2015 and had planned to list on the Nasdaq under the symbol CSTX. Citi and Credit Suisse were set to be the joint...read more

Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH biotech, Cirius Therapeutics (CSTX), is in the IPO pipeline, but before this year, the last biotech IPO targeting NASH came in...read more

After years of disappointing clinical trials for nonalcoholic steatohepatitis (NASH), an often fatal liver disease associated with obesity and diabetes, there are a number of promising late-stage clinical trials underway, including two being conducted by pending biotech IPOs Cirius Therapeutics (CSTX) and Genfit (GNFT). NASH affects 20 million people with no FDA-approved...read more

As expected, no IPOs priced this past week. And thanks to the government shutdown, no IPOs launched roadshows, either. However, new IPOs entered the public pipeline, with initial filings from biotechs Alector (ALEC) and Anchiano Therapeutics (ANCN), Blackstone subprime lender Exeter Finance (XTF), and large SPAC ...read more